These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25496288)

  • 21. Gait Speed as a Guide for Blood Pressure Targets in Older Adults: A Modeling Study.
    Odden MC; Moran AE; Coxson PG; Peralta CA; Goldman L; Bibbins-Domingo K
    J Am Geriatr Soc; 2016 May; 64(5):1015-23. PubMed ID: 27225357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exaggerated exercise blood pressure response in middle-aged men as a predictor of future blood pressure: a 10-year follow-up.
    Ito K; Iwane M; Miyai N; Uchikawa Y; Mugitani K; Mohara O; Shiba M; Arita M
    Clin Exp Hypertens; 2016; 38(8):696-700. PubMed ID: 27936961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
    Tscheulin DK; Drevs F
    Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis.
    Singh G; Miller JD; Huse DM; Pettitt D; D'Agostino RB; Russell MW
    J Rheumatol; 2003 Apr; 30(4):714-9. PubMed ID: 12672188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe.
    Hansson L; Lloyd A; Anderson P; Kopp Z
    Blood Press; 2002; 11(1):35-45. PubMed ID: 11926349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
    Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Favorable Cardiovascular Risk Profile Is Associated With Lower Healthcare Costs and Resource Utilization: The 2012 Medical Expenditure Panel Survey.
    Valero-Elizondo J; Salami JA; Ogunmoroti O; Osondu CU; Aneni EC; Malik R; Spatz ES; Rana JS; Virani SS; Blankstein R; Blaha MJ; Veledar E; Nasir K
    Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):143-53. PubMed ID: 26941417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A short-term cost-effectiveness analysis of hypertension treatment in Greece.
    Athanasakis K; Souliotis K; Tountas Y; Yfantopoulos J; Kyriopoulos J; Hatzakis A
    Hellenic J Cardiol; 2014; 55(3):197-203. PubMed ID: 24862611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [2013 Ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals (summary). Joint recommendations from the International Society for Chronobiology (ISC), American Association of Medical Chronobiology and Chronotherapeutics (AAMCC), Spanish Society of Applied Chronobiology, Chronotherapy, and Vascular Risk (SECAC), Spanish Society of Atherosclerosis (SEA), and Romanian Society of Internal Medicine (RSIM)].
    Hermida RC; Smolensky MH; Ayala DE; Portaluppi F; Crespo JJ; Fabbian F; Haus E; Manfredini R; Mojón A; Moyá A; Piñeiro L; Ríos MT; Otero A; Balan H; Fernández JR
    Clin Investig Arterioscler; 2013; 25(2):74-82. PubMed ID: 23849214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic impact of hypoglycemia among insulin-treated patients with diabetes.
    Sussman M; Sierra JA; Garg S; Bode B; Friedman M; Gill M; Kaufman F; Vigersky R; Menzin J
    J Med Econ; 2016 Nov; 19(11):1099-1106. PubMed ID: 27292016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals.
    ; ; ; ; ; Hermida RC; Smolensky MH; Ayala DE; Portaluppi F
    Chronobiol Int; 2013 Apr; 30(3):355-410. PubMed ID: 23517220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic impact of the BP DownShift Program on blood pressure control among commercial driver license employees.
    Greene BL; Miller JD; Brown TM; Harshman RS; Richerson GT; Doyle JJ
    J Occup Environ Med; 2009 May; 51(5):542-53. PubMed ID: 19365286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis.
    Verguet S; Olson ZD; Babigumira JB; Desalegn D; Johansson KA; Kruk ME; Levin CE; Nugent RA; Pecenka C; Shrime MG; Memirie ST; Watkins DA; Jamison DT
    Lancet Glob Health; 2015 May; 3(5):e288-96. PubMed ID: 25889470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2017 May; 35(5):922-944. PubMed ID: 28141660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial.
    Mancia G; Kjeldsen SE; Zappe DH; Holzhauer B; Hua TA; Zanchetti A; Julius S; Weber MA
    Eur Heart J; 2016 Mar; 37(12):955-64. PubMed ID: 26590384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?
    Bhatt H; Ghazi L; Calhoun D; Oparil S
    Curr Cardiol Rep; 2016 Oct; 18(10):98. PubMed ID: 27566331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare Costs Attributable to Hypertension: Canadian Population-Based Cohort Study.
    Weaver CG; Clement FM; Campbell NR; James MT; Klarenbach SW; Hemmelgarn BR; Tonelli M; McBrien KA;
    Hypertension; 2015 Sep; 66(3):502-8. PubMed ID: 26169049
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.